Vickie and Jack Farber Institute for Neuroscience | Strategic Alliance Partners

Stratification of the cohort into low- and elevated-cardiovascular risk groups revealed no differences in cardiovascular adverse events with repetitive DHE; however, elevated-risk patients had higher mean arterial blood pressure.

Joe Kardine, MS, OTR, CBIS, the clinical program manager at the Jefferson Center for Neurorestoration, discussed the influx of new neurorestorative technology and the future of treating patients with functional loss.

The clinical program manager at the Jefferson Center for Neurorestoration provided commentary on the state of neurorestoration and constant transformation of the space. [WATCH TIME: 3 minutes]

When hydromethylthionine mesylate was compared with publicly available placebo decline data, the treatment effects of cognitive and functional decline are about 3-fold larger over 18 months.

The clinical program manager at the Jefferson Center for Neurorestoration discussed a new approach to restoring arm function using a powered arm brace and muscle stimulation system.

The clinical program manager at the Jefferson Center for Neurorestoration provided insight on a new myoelectric device designed for restoration of independent arm function in those with neurological diseases. [WATCH TIME: 4 minutes]

Despite the availability of medications to relieve OFF episodes in Parkinson disease, widespread adoption of on-demand therapies has been less-than-ideal, marking the need to shift the treatment paradigm in PD.

The chief of emergency medical services at Jefferson Health spoke about the operation of the Jefferson mobile stroke unit in the field, and the impact that the onset of the COVID-19 pandemic had on launching the program. [WATCH TIME: 3 minutes]

The executive director of the Bensalem Rescue Squad spoke specifically to how the MSU has shifted the paradigm of care that EMS can provide to individuals in the community. [WATCH TIME: 4 minutes]

The chief of emergency medical services at Jefferson Health shared his perspective on the first 2 years of the Jefferson MSU’s use and what takeaways he has gleaned from the experience. [WATCH TIME: 3 minutes]

Two experts at Jefferson Health discuss several topics related to advances in neurosurgery, technology, and the future of minimally invasive procedures.

Mind Moments®, a podcast from NeurologyLive®, brings you an exclusive interview with Dhanashri P. Miskin, MD. [LISTEN TIME: 39 minutes]

A practical approach to initiating and tapering corticosteroids, and the considerations in the selection and monitoring parameters of steroid-sparing agents are crucial to the care of myasthenia gravis.

Karl Doghramji, MD, the medical director of the Jefferson Sleep Disorders Center at the Vickie and Jack Farber Institute for Neuroscience of Jefferson Health, looks ahead to the needs for sleep care heading into 2022.

The medical director of the Jefferson Sleep Disorders Center at the Vickie and Jack Farber Institute for Neuroscience of Jefferson Health offered his insight into the current state of care for sleep and the progress made this year.

Mind Moments™, a podcast from NeurologyLive®, brings you an exclusive interview with Karl Doghramji, MD, FAASM, DFAPA.

William B. Young, MD, codirector of Inpatient Program at Jefferson Headache Center, discussed how the clinical and patient communities can squash misguided migraine stigmas.

The headache specialist at Jefferson Headache Center discussed the need to revamp the education process for migraine care and how much time residents spend learning about the disease. [WATCH TIME: 2 minutes]

The headache specialist at Jefferson Headache Center discussed the array of issues patients with migraine face and why her personal experience may resonate with patients. [WATCH TIME: 3 minutes]

At the Third International Congress on the Future of Neurology, experts in the care of sleep medicine offered insight into sleep and the glymphatic system’s roles in the development of dementias.

The web-implemented algorithm misclassified and misdiagnosed seizures in only 16.8% of the patients with epilepsy—lower than rates previously reported in the literature.

Maromi Nei, MD, and Michael R. Sperling, MD, shared their insight on the novel inventory tool for predicting sudden unexpected death in epilepsy and their recently published work.

The SUDEP-3 outperformed the prior SUDEP-7 variation on all measures, and simplifies the risk assessment with a 3-item weighted scoring while enhancing the clinical practicality.

The associate professor and director of the Headache Medicine Fellowship Program at Thomas Jefferson University discussed the role of clinicians in determining migraine treatment eligibility.

The associate professor and director of the Headache Medicine Fellowship Program at Thomas Jefferson University discussed the barriers to the use of preventive medicines.

The associate professor and director of the Headache Medicine Fellowship Program at Thomas Jefferson University discussed treatment optimization for patients with migraine and raising overall awareness for preventive treatments.

The associate professor and director of the Headache Medicine Fellowship Program at Thomas Jefferson University detailed the ways clinicians can tailor their treatment regimens better.

"Mind Moments," a podcast from NeurologyLive, brings you exclusive interviews with Stephanie J. Nahas, MD; Bruce Cree, MD, PhD, MAS; Sana Somani, MD, MBBS; Hubert Fernandez, MD; Daniel Ontaneda, MD, PhD; and Richard Gershon, PhD.

The associate professor and director of the Headache Medicine Fellowship Program at Thomas Jefferson University detailed the reasons fremanezumab stands out among a crowded migraine treatment landscape.

Patients with a previous history of cardiovascular risks experienced similarly low number of cardiovascular events with treatment of fremanezumab compared with placebo.